Market Overview

UPDATE: JP Morgan Raises PT on Pfizer on Takeaways from Meeting with Management

Share:
Related PFE
Bayer's Latest Stage 2 Trial Could Be A Boon For Shares
S&P 500 Index Futures Trading Lower In Choppy, Volatile Session
Should You Sell GE, AT&T, Pfizer? Check Weekly Charts (Investor's Business Daily)

JP Morgan maintained Pfizer (NYSE: PFE) with an Overweight rating and raised the price target from $31.00 to $32.00.

JP Morgan analyst Chris Schott commented, "Overall, we see several interesting assets in Pfizer's pipeline beyond Eliquis and Xeljanz (most notably PD-991) and believe we are beginning to see results from the company's refocused R&D efforts. In addition, we continue to believe that a larger break-up of Pfizer remains a distinct possibility, particularly if the company's core pharmaceutical portfolio is able to generate sustained growth over time."

Pfizer closed at $27.99 on Tuesday.

Latest Ratings for PFE

DateFirmActionFromTo
Aug 2015JefferiesMaintainsBuy
Jun 2015JefferiesInitiates Coverage onOverweight
Jun 2015Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters